Bioventus Delivers $14.8M Q4 Profit, Guides 2026 EPS To $0.73–$0.77
Bioventus posted Q4 profit of $14.8 million, or $0.21 per share ($0.24 adjusted), on revenue of $157.9 million. It swung to a full-year net profit of $22.7 million on $568.1 million revenue and forecast 2026 EPS of $0.73–$0.77 with $600–$610 million in sales.
1. Q4 Financial Performance
Bioventus reported net income of $14.8 million for the fourth quarter, equating to $0.21 per share, or $0.24 when adjusted for non-recurring costs. Revenue for the period reached $157.9 million, reflecting the company’s continued strength in core product lines.
2. Fiscal 2025 Results
For the full fiscal year, Bioventus swung to a net profit of $22.7 million, or $0.33 per share, on annual revenue of $568.1 million, marking a return to profitability after prior losses. This performance underscores improved operational efficiencies and cost controls.
3. 2026 Financial Guidance
The company provided guidance for fiscal 2026, projecting adjusted earnings of $0.73 to $0.77 per share and revenue between $600 million and $610 million. This outlook reflects expectations for steady organic growth and potential contributions from recent product launches.
4. Stock Performance Trends
Bioventus shares have climbed 14% since the start of the year, recovering from a 16% decline over the past 12 months. The recent earnings beat and optimistic guidance have contributed to heightened investor interest.